) The Radiation Therapy Oncology Group (RTOG) has committed itself as a Research Base for the Community Clinical Oncology Program (CCOP). This application documents the current RTOG cancer control organization within which the 25 CCOP members participate in the areas of cancer treatment studies and cancer prevention and control scientific proposals. The RTOG, with its experience and expertise in local-regional cancer treatment and control, will continue to utilize the CCOP network as one of the major components of its cancer control research program, which focuses on intervention studies in the cured and potentially curable cancer patient. This application documents the cancer prevention and control activity within the RTOG manifested by the established chemoprevention experience program, the approved and proposed intervention studies in head and neck, brain and gastrointestinal cancers, as well as studies addressing symptom control. To meet the needs of an expanded cancer control program and to complete the integration of CCOP members into the RTOG, a Vice Chair for Cancer Control and a CCOP Principal Investigators' (PI) Committee Chair have been established to c o ordinate cancer prevention and control activities within the Chemoprevention, Late Effects, Quality of Life, Epidemiology and Special Populations Committees, as well as Biostatistics, Economic Impact and Research Associates support units. A Steering Committee composed of CCOP designees to these committees, the CCOP PI's Chair and the Vice Chair for Cancer Control, evaluate and set priorities for all cancer prevention and control studies. The CCOPs are evaluated by the CCOP Membership Evaluation Committee to insure adherence to all NCI requirements. The Administrative, Protocol, Quality Assurance and Data Management Units of RTOG are utilized in initiating these cancer control trials and the quality assurance procedures, including on-site audits, are applied to the community network. The goal is for the continued integration of the CCOPs into the RTOG to insure all members the opportunity to participate in all facts of RTOG activities in order to facilitate the transference of the latest scientific information into the community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA037422-11S2
Application #
6052937
Study Section
Special Emphasis Panel (ZCA1 (J2))
Project Start
1994-06-01
Project End
2000-05-31
Budget Start
1998-06-01
Budget End
1999-05-31
Support Year
11
Fiscal Year
1999
Total Cost
Indirect Cost
Name
American College of Radiology
Department
Type
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Ali, Arif N; Zhang, Peixin; Yung, W K Alfred et al. (2018) NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients. J Neurooncol 137:39-47
Lawrence, Yaacov R; Moughan, Jennifer; Magliocco, Anthony M et al. (2018) Expression of the DNA repair gene MLH1 correlates with survival in patients who have resected pancreatic cancer and have received adjuvant chemoradiation: NRG Oncology RTOG Study 9704. Cancer 124:491-498
Raman, Srinivas; Ding, Keyue; Chow, Edward et al. (2018) Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. Qual Life Res 27:1089-1098
Dormer, James D; Halicek, Martin; Ma, Ling et al. (2018) Convolutional Neural Networks for the Detection of Diseased Hearts Using CT Images and Left Atrium Patches. Proc SPIE Int Soc Opt Eng 10575:
Dormer, James D; Ma, Ling; Halicek, Martin et al. (2018) Heart Chamber Segmentation from CT Using Convolutional Neural Networks. Proc SPIE Int Soc Opt Eng 10578:
Michalski, Jeff M; Moughan, Jennifer; Purdy, James et al. (2018) Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol 4:e180039
Seider, Michael J; Pugh, Stephanie L; Langer, Corey et al. (2018) Randomized phase III trial to evaluate radiopharmaceuticals and zoledronic acid in the palliation of osteoblastic metastases from lung, breast, and prostate cancer: report of the NRG Oncology RTOG 0517 trial. Ann Nucl Med 32:553-560
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2018) Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol :JCO2018788620
Regine, William F; Winter, Kathryn; Abrams, Ross A et al. (2018) Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Adv Radiat Oncol 3:154-162
Konski, Andre; Bhargavan, Mytheryi; Owen, Jean et al. (2018) An Economic Analysis of Radiation Therapy Oncology Group 94-10: Cost-Efficacy of Concurrent vs. Sequential Chemoradiotherapy. J Radiat Oncol 7:195-201

Showing the most recent 10 out of 326 publications